NCT06853457Completed
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases: from Lesion-targeted to Patient-targeted Prediction
Source: ClinicalTrials.gov · Last updated 3 Mar 2025
Brief summary (registry, in English)
To develop and validate a CT-based transfer learning radiomics model for predicting response to initial TAE in GEP-NETLM patients and compare its performance with traditional radiomics and clinical models.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 257 (actual)
- First submitted
- 23 Feb 2025
- Start date
- 1 Jan 2014
- Primary completion date
- 30 Sept 2022
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06853457
What you commit to
- Study type: Observational
- Participants enrolled: 257
- From 1 Jan 2014 to the primary completion date, 30 Sept 2022
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (a) Neuroendocrine carcinoma (NEC) or other malignancies. (b) Received other liver metastasis treatments. (c) Lack of Multi-phase ceCT scans records. (d) CT images with artifacts or no visible lesions.
Who the study is looking for
- (a) Clinical diagnosed as gastroenteropancreatic neuroendocrine tumor liver metastases; (b) Received initial transarterial embolization therapy; (c) Underwent multi-phase ceCT scans pre-TAE (≤1 month) and post-TAE (4-6 weeks).
Age in the registry: 18 years to 78 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.